TC |
Stat |
Stk |
Ins |
Fil |
+d |
+w |
+m |
+q |
+h |
+y |
avg |
|---|---|---|---|---|---|---|---|---|---|---|---|
| P | %ret | 1 | 1 | 1 | 5 | 9 | 17 | -34 | 0 | 0 | -1 |
| P | %wins | 100 | 100 | 100 | 0 | 75 |
Filing Date |
T Date |
Ticker |
Issuer | Inc | Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
11/29/22 16:11 | 11/25/22 | CRDF | Cardiff Oncology, Inc. | DE | Health | BioPrd | Biological Products, (No Diag | Erlander Mark | CA | DO | CEO | P | 14 | 1.43 | 0 | 10 | 69 | 24 | D | ||||||||||||||
3/23/21 12:24 | 3/23/21 | CRDF | Cardiff Oncology, Inc. | DE | Health | BioPrd | Biological Products, (No Diag | Erlander Mark | CA | O | CEO | P | 10 | 10.34 | 0 | 1 | 7 | 14 | D | ||||||||||||||
5/18/20 16:17 | 5/14/20 | CRDF | Cardiff Oncology, Inc. | DE | Health | BioPrd | Biological Products, (No Diag | Erlander Mark | CA | O | CEO | P | 10 | 1.43 | 0 | 7 | 110 | 13 | D | ||||||||||||||
12/15/16 17:00 | 12/14/16 | TROV | Trovagene, Inc. | DE | Health | BioPrd | Biological Products, (No Diag | Erlander Mark | CA | O | Chief Sc | P | 10 | 2.08 | 1 | 5 | New | 5 | D | -51 | -62 | -56 | -58 | -34 | -31 | -17 | -17 | 5 | 9 | 17 | -34 |
| D | Derivative transaction in filing (usually option exercise) |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| A | Amended filing |
| E | Error detected in filing |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |